Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (381-390 of 609) with videos related to

Pageof 61
Sort By:
Journal of Clinical Immunology|December 29, 2023
IL4Rα and IL17A Blockade Rescue Autoinflammation in SOCS1 HaploinsufficiencyConor Gruber, Angelica Lee, Sofija Buta, et al.
Annals of the Rheumatic Diseases|April 22, 2016
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)Arthur Kavanaugh, Lluis Puig, Alice B Gottlieb, et al.
The British Journal of Dermatology|March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3K A Papp, K B Gordon, R G Langley, et al.
Human Molecular Genetics|January 1, 1994
Complete androgen insensitivity due to mutations in the probable alpha-helical segments of the DNA-binding domain in the human androgen receptorL K Beitel, L Prior, D M Vasiliou, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working GroupLourdes M Perez-Chada, Sanminder Singh, Kristina Callis-Duffin, et al.
Journal of the American Academy of Dermatology|September 30, 2019
Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
Journal of the American Academy of Dermatology|June 23, 2009
Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonistsAdam Asarch, Alice B Gottlieb, Jin Lee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 6, 2023
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease managementLluís Puig, Siew Eng Choon, Alice B Gottlieb, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2016
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studiesA B Gottlieb, J-P Lacour, N Korman, et al.
Journal of Cutaneous Pathology|February 1, 1991
Fixed drug eruptions: evidence for a cytokine-mediated processB R Smoller, A D Luster, J F Krane, et al.
Pageof 61

Showing results (381-390 of 609) with videos related to

Sort By:
Pageof 61
Journal of Clinical Immunology|December 29, 2023
IL4Rα and IL17A Blockade Rescue Autoinflammation in SOCS1 HaploinsufficiencyConor Gruber, Angelica Lee, Sofija Buta, et al.
Annals of the Rheumatic Diseases|April 22, 2016
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)Arthur Kavanaugh, Lluis Puig, Alice B Gottlieb, et al.
The British Journal of Dermatology|March 1, 2018
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3K A Papp, K B Gordon, R G Langley, et al.
Human Molecular Genetics|January 1, 1994
Complete androgen insensitivity due to mutations in the probable alpha-helical segments of the DNA-binding domain in the human androgen receptorL K Beitel, L Prior, D M Vasiliou, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working GroupLourdes M Perez-Chada, Sanminder Singh, Kristina Callis-Duffin, et al.
Journal of the American Academy of Dermatology|September 30, 2019
Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)Mark G Lebwohl, Craig L Leonardi, Nehal N Mehta, et al.
Journal of the American Academy of Dermatology|June 23, 2009
Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonistsAdam Asarch, Alice B Gottlieb, Jin Lee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 6, 2023
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease managementLluís Puig, Siew Eng Choon, Alice B Gottlieb, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2016
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studiesA B Gottlieb, J-P Lacour, N Korman, et al.
Journal of Cutaneous Pathology|February 1, 1991
Fixed drug eruptions: evidence for a cytokine-mediated processB R Smoller, A D Luster, J F Krane, et al.
Pageof 61